Cancer Cell
Volume 21, Issue 6, 12 June 2012, Pages 723-737
Journal home page for Cancer Cell

Article
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

https://doi.org/10.1016/j.ccr.2012.05.024Get rights and content
Under an Elsevier user license
open archive

Summary

Knowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells while sparing normal cells. Lenalidomide is an active agent in the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), but its mechanism of action is unknown. Lenalidomide kills ABC DLBCL cells by augmenting interferon β (IFNβ) production, owing to the oncogenic MYD88 mutations in these lymphomas. In a cereblon-dependent fashion, lenalidomide downregulates IRF4 and SPIB, transcription factors that together prevent IFNβ production by repressing IRF7 and amplify prosurvival NF-κB signaling by transactivating CARD11. Blockade of B cell receptor signaling using the BTK inhibitor ibrutinib also downregulates IRF4 and consequently synergizes with lenalidomide in killing ABC DLBCLs, suggesting attractive therapeutic strategies.

Highlights

► Lenalidomide kills ABC DLBCLs by decreasing expression of IRF4 and SPIB ► IRF4 and SPIB maintain ABC DLBCL viability ► IRF4 and SPIB block toxic IFNβ production while enhancing prosurvival NF-κB activity ► Lenalidomide and BCR pathway drugs synergize to inhibit IRF4 and kill ABC DLBCLs

Cited by (0)

7

These authors contributed equally to this work

8

Present address: Boğaziçi University, Department of Molecular Biology and Genetics, Laboratory of Genome Regulation, Kuzey Park Binasi, 3.Kat, Bebek 34342, Istanbul, Turkey